All In Biotech

Drug Trial Radar · NCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 14, 2025

Primary completion

Nov 29, 2028

Study completion Apr 19, 2030

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Conditions

  • IgAN
  • IgAVN
  • Immunoglobulin A Nephropathy
  • Immunoglobulin A Vasculitis Associated Nephritis
  • Henoch-schonlein Purpura Nephritis
  • IgA Vasculitis

Interventions

  • RavulizumabDrug

    Participants will receive Ravulizumab via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR) at Week 34Time frame: Baseline, Week 34

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Palo Alto, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    London, Ontario, Canada · Not yet recruiting

  • Research Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Berlin, Germany · Not yet recruiting

  • Research Site

    Essen, Germany · Not yet recruiting

  • Research Site

    Genova, Italy · Recruiting

  • Research Site

    Roma, Italy · Recruiting

  • Research Site

    Torino, Italy · Recruiting

  • Research Site

    Wakayama, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Almería, Spain · Not yet recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Seville, Spain · Recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.